참고문헌
- Arshad MI, Piquet-Pellorce C, Samson M (2012). IL-33 and HMGB1 alarmins: sensors of cellular death and their involvement in liver pathology. Liver Int, 32, 1200-10. https://doi.org/10.1111/j.1478-3231.2012.02802.x
- Bergis D, Kassis V, Ranglack A, et al (2013). High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma. Transl Oncol, 6, 311-8. https://doi.org/10.1593/tlo.12418
- Bonilla WV, Frohlich A, Senn K, et al (2012). The alarmin interleukin-33 drives protective antiviral CD8 (+). T cell responses. Science, 335, 984-9. https://doi.org/10.1126/science.1215418
- Bourgeois E, Van LP, Samson M, et al (2009). The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol, 39, 1046–55. https://doi.org/10.1002/eji.200838575
- Chackerian AA, Oldham ER, Murphy EE, et al (2007). IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol, 179, 2551–5. https://doi.org/10.4049/jimmunol.179.4.2551
- Chen SF, Nieh S, Jao SW, et al (2013). The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J Pathol, 231, 180-9. https://doi.org/10.1002/path.4226
- Dobrzanski MJ, Reome JB, Hylind JC, et al (2006). CD8-mediated type 1 antitumor responses selectively modulate endogenous differentiated and nondifferentiated T cell localization, activation, and function in progressive breast cancer. J Immunol, 177, 8191-201. https://doi.org/10.4049/jimmunol.177.11.8191
- Gangemi S, Allegra A, Profita M, et al (2013). Decreased plasma levels of IL-33 could contribute to the altered function of Th2 lymphocytes in patients with polycythemia vera and essential thrombocythemia. Cancer Invest, 31, 212-3. https://doi.org/10.3109/07357907.2013.764566
- Hu LA, Fu Y, Zhang DN, et al (2013). Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer. Asian Pac J Cancer Prev, 14, 2563-6. https://doi.org/10.7314/APJCP.2013.14.4.2563
- Humphreys NE, Xu D, Hepworth MR, et al (2008). IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol, 180, 2443-9. https://doi.org/10.4049/jimmunol.180.4.2443
- Jovanovic IP, Pejnovic NN, Radosavljevic GD, et al (2014). Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer, 134, 1669-82. https://doi.org/10.1002/ijc.28481
- Jovanovic I, Radosavljevic G, Mitrovic M, et al (2011). ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma. Eur J Immuno, l41, 1902-12. https://doi.org/10.1002/eji.201141417
- Kakkar R and Lee RT (2008). The IL-33/ST2 pathway:therapeutic target and novel biomarker. Nat Rev Drug Discov, 7, 827–40. https://doi.org/10.1038/nrd2660
- Liew FY, Pitman N, McInnes IB (2010). Disease-associated functions of IL-33: the new kid in the IL-1 family, Nat Rev Immunol, 10, 103-10. https://doi.org/10.1038/nri2692
- Lopetuso LR, Scaldaferri F, Pizarro TT (2012). Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis. Fibrogenesis Tissue Repair, 5, 18. https://doi.org/10.1186/1755-1536-5-18
- Naumnik W, Naumnik B, Niewiarowska K, et al (2012). Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer?Exp Oncol, 34, 348-53.
- Oshikawa K, Yanagisawa K, Ohno S, et al (2002). Expression of ST2 in helper T lymphocytes of malignant pleural effusions. Am J Respir Crit Care Med, 165, 1005-9. https://doi.org/10.1164/ajrccm.165.7.2105109
- Roy A, Ganesh G, Sippola H, et al (2014). Mast Cell Chymase Degrades the Alarmins Heat Shock Protein 70, Biglycan, HMGB1, and Interleukin-33 (IL-33). and Limits Dangerinduced Inflammation. J Biol Chem, 289, 237-50. https://doi.org/10.1074/jbc.M112.435156
- Santulli P, Even M, Chouzenoux S, et al (2013). Profibrotic interleukin-33 is correlated with uterine leiomyoma tumour burden. Hum Reprod, 28, 2126-33. https://doi.org/10.1093/humrep/det238
- Schmitz J, Owyang A, Oldham E, et al (2005). IL-33, an interleukin-1-likecytokine that signals via the IL-1 receptorrelated protein ST2 and induces Thelper type 2-associated cytokines. Immunity, 23, 479–90. https://doi.org/10.1016/j.immuni.2005.09.015
- Sun P, Ben Q, Tu S, et al (2011). Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci, 56, 3596-601. https://doi.org/10.1007/s10620-011-1760-5
- Walzl G, Matthews S, Kendall S, et al (2001). Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)-but not Th1-driven immunopathology. J Exp Med, 193, 785-92. https://doi.org/10.1084/jem.193.7.785
- Williams MA, Bevan MJ (2007). Effector and memory CTL differentiation, Annu Rev Immunol, 25, 171-92. https://doi.org/10.1146/annurev.immunol.25.022106.141548
- Zhang P, Liu XK, Chu Z, et al (2012). Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications. J Int Med Res, 40, 1654-61. https://doi.org/10.1177/030006051204000504
피인용 문헌
- IL-33 Promotes Gastric Cancer Cell Invasion and Migration Via ST2–ERK1/2 Pathway vol.60, pp.5, 2015, https://doi.org/10.1007/s10620-014-3463-1
- T cells in resected hepatocellular carcinoma prolong patient survival vol.61, pp.6, 2015, https://doi.org/10.1002/hep.27728
- A novel isoform of IL-33 revealed by screening for transposable element promoted genes in human colorectal cancer vol.12, pp.7, 2017, https://doi.org/10.1371/journal.pone.0180659
- Overexpression of interleukin-33 is associated with poor prognosis of patients with glioma vol.127, pp.3, 2017, https://doi.org/10.1080/00207454.2016.1175441
- An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer vol.114, pp.1, 2016, https://doi.org/10.1038/bjc.2015.433